U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C2H4NO2.Na
Molecular Weight 97.0484
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SODIUM GLYCINATE

SMILES

[Na+].NCC([O-])=O

InChI

InChIKey=WUWHFEHKUQVYLF-UHFFFAOYSA-M
InChI=1S/C2H5NO2.Na/c3-1-2(4)5;/h1,3H2,(H,4,5);/q;+1/p-1

HIDE SMILES / InChI

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C2H4NO2
Molecular Weight 74.0587
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Glycine (Cly) is a natural amino acid neurotransmitter that acts as a co-agonist at Glutamate [NMDA] receptors in the brain and is an activator of glycine receptors, GLRA1-3, GLRB. The abnormal Gly levels have been implicated in neuropsychiatric disorders. Alterations in Gly levels are implicated in several diseases of the central nervous system. Glycine was studied in phase II of clinical trials in patients with schizophrenia. The results have shown that using of glycine was associated with reduced symptoms with promising effect sizes and a possibility of improvement in cognitive function. Besides, glycine was also studied in clinical trials phase II in children with cystic fibrosis. The clinical, spirometric and inflammatory status of subjects with cystic fibrosis improved after just 8 weeks of glycine intake, suggesting that this amino acid might constitute a novel therapeutic tool for these patients. In addition, Gly was proposed as a biomarker for brain tumor malignancy. Glycine is a component of a nutrients mixture for peripheral administration to well-nourished mildly catabolic adult patients who require only short-term parenteral nutrition.

CNS Activity

Curator's Comment: Known to be CNS non-penetrant in rabbit. Human data not available.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
Unknown

Approved Use

Unknown
Palliative
Unknown

Approved Use

Unknown
Palliative
Unknown

Approved Use

Unknown
Preventing
FREAMINE III 8.5%

Approved Use

Aminosyn, Sulfite-Free, (a crystalline amino acid solution) infused with dextrose by peripheral vein infusion is indicated as a source of nitrogen in the nutritional support of patients with adequate stores of body fat, in whom, for short periods of time, oral nutrition cannot be tolerated, is undesirable, or inadequate. SUPPLEMENTAL ELECTROLYTES, IN ACCORDANCE WITH THE PRESCRIPTION OF THE ATTENDING PHYSICIAN, MUST BE ADDED TO AMINOSYN SOLUTIONS WITHOUT ELECTROLYTES. Aminosyn can be administered peripherally with dilute (5 to 10%) dextrose solution and I.V. fat emulsion as a source of nutritional support. This form of nutritional support can help to preserve protein and reduce catabolism in stress conditions where oral intake is inadequate. When administered with concentrated dextrose solutions with or without fat emulsions, Aminosyn is also indicated for central vein infusion to prevent or reverse negative nitrogen balance in patients where: (a) the alimentary tract, by the oral, gastrostomy or jejunostomy route cannot or should not be used; (b) gastrointestinal absorption of protein is impaired; (c) metabolic requirements for protein are substantially increased as with extensive burns and (d) morbidity and mortality may be reduced by replacing amino acids lost from tissue breakdown, thereby preserving tissue reserves, as in acute renal failure.

Launch Date

1971
PubMed

PubMed

TitleDatePubMed
Sustained L-type calcium currents in dissociated deep dorsal horn neurons of the rat: characteristics and modulation.
2001
Identification of genetic variants (g789C>T and G111S) in the human HSPB2 gene.
2001
Identification of the first reported splice site mutation (IVS7-1G-->A) in the aminomethyltransferase (T-protein) gene (AMT) of the glycine cleavage complex in 3 unrelated families with nonketotic hyperglycinemia.
2001
Is the Ala138Gly alteration of MEFV gene important for amyloidosis?
2001
Mutant mice as a model for cerebellar ataxia.
2001 Apr
Selective cleavage of BLM, the bloom syndrome protein, during apoptotic cell death.
2001 Apr 13
The folate cycle and disease in humans.
2001 Feb
Functional projection distances of spinal interneurons mediating reciprocal inhibition during swimming in Xenopus tadpoles.
2001 Feb
Distribution of transcripts for the brain-specific GDP/GTP exchange factor collybistin in the developing mouse brain.
2001 Feb
High-dose intravenous infusion of irrigating fluids containing glycine and mannitol in the pig.
2001 Feb
Microdialysis in Parkinsonian patient basal ganglia: acute apomorphine-induced clinical and electrophysiological effects not paralleled by changes in the release of neuroactive amino acids.
2001 Feb
Homeodomain leucine zipper proteins bind to the phosphate response domain of the soybean VspB tripartite promoter.
2001 Feb
A novel syndrome affecting multiple mitochondrial functions, located by microcell-mediated transfer to chromosome 2p14-2p13.
2001 Feb
Hamster sperm glycine receptor: evidence for its presence and involvement in the acrosome reaction.
2001 Feb
Biosynthesis of threonine from homoserine by mixed rumen microorganisms: an in vitro study.
2001 Feb
Trimethylamine oxide counteracts effects of hydrostatic pressure on proteins of deep-sea teleosts.
2001 Feb 15
Isolation of a new melanoma antigen, MART-2, containing a mutated epitope recognized by autologous tumor-infiltrating T lymphocytes.
2001 Feb 15
Evidence for microvesicular storage and release of glycine in rodent pinealocytes.
2001 Feb 16
Replacement of the axial histidine ligand with imidazole in cytochrome c peroxidase. 1. Effects on structure.
2001 Feb 6
Critical role of the residue size at position 87 in H2O2- dependent substrate hydroxylation activity and H2O2 inactivation of cytochrome P450BM-3.
2001 Feb 9
Ehlers-Danlos syndrome type IV with a unique point mutation in COL3A1 and familial phenotype of myocardial infarction without organic coronary stenosis.
2001 Jan
New polymorphisms in the interleukin-10 gene--relationships to myocardial infarction.
2001 Jan
An HphI polymorphism in the E-selectin gene is associated with premature coronary artery disease.
2001 Jan
Generalized dystrophic epidermolysis bullosa: identification of a novel, homozygous glycine substitution, G2031S, in exon 73 of COL7A1 in monozygous triplets.
2001 Jan
Determination of bile acids in biological fluids by liquid chromatography-electrospray tandem mass spectrometry.
2001 Jan
cAMP-dependent presynaptic regulation of spontaneous glycinergic IPSCs in mechanically dissociated rat spinal cord neurons.
2001 Jan
Postsynaptic currents in deep cerebellar nuclei.
2001 Jan
Slow dorsal-ventral rhythm generator in the lamprey spinal cord.
2001 Jan
Excitatory amino acid concentrations in ventricular cerebrospinal fluid after severe traumatic brain injury in infants and children: the role of child abuse.
2001 Jan
Microdialysis study of amino acid neurotransmitters in the spinal dorsal horn of patients undergoing microsurgical dorsal root entry zone lesioning. Technical note.
2001 Jan
N-methyl-D-aspartate receptors mediating hippocampal noradrenaline and striatal dopamine release display differential sensitivity to quinolinic acid, the HIV-1 envelope protein gp120, external pH and protein kinase C inhibition.
2001 Jan
Disorders of membrane channels or channelopathies.
2001 Jan
Spatial scale and cellular substrate of contrast adaptation by retinal ganglion cells.
2001 Jan
Analysis of glycoconjugate patterns of normal and hormone-induced dysplastic Noble rat prostates, and an androgen-independent Noble rat prostate tumor, by lectin histochemistry and protein blotting.
2001 Jan 1
Regulation of a mammalian Shaker-related potassium channel, hKv1.5, by extracellular potassium and pH.
2001 Jan 12
Intensity-dependent, rapid activation of presynaptic metabotropic glutamate receptors at a central synapse.
2001 Jan 15
Three pairs of cysteine residues mediate both redox and zn2+ modulation of the nmda receptor.
2001 Jan 15
Familial Tetralogy of Fallot caused by mutation in the jagged1 gene.
2001 Jan 15
Intracellular folding pathway of the cystine knot-containing glycoprotein hormone alpha-subunit.
2001 Jan 16
Chemical rescue of phosphoryl transfer in a cavity mutant: a cautionary tale for site-directed mutagenesis.
2001 Jan 16
Virol A, a toxic trans-polyacetylenic alcohol of Cicuta virosa, selectively inhibits the GABA-induced Cl(-) current in acutely dissociated rat hippocampal CA1 neurons.
2001 Jan 19
Ultrastructural evidence for direct projections from the pontine micturition center to glycine-immunoreactive neurons in the sacral dorsal gray commissure in the cat.
2001 Jan 22
The p57Kip2 cyclin kinase inhibitor is expressed by a restricted set of amacrine cells in the rodent retina.
2001 Jan 22
Effect of extracellular long-time microperfusion of high concentrations of glutamate and glycine on picrotoxin seizure thresholds in the hippocampus of freely moving rats.
2001 Jan 5
Differential roles of two conserved glycine residues in the fusion peptide of Semliki Forest virus.
2001 Jan 5
Genetics, an alternative way to discover, characterize and understand ion channels.
2001 Jan-Feb
Functional reconstitution and characterization of recombinant human alpha 1-glycine receptors.
2001 Jun 15
Glycine reduces novelty- and methamphetamine-induced locomotor activity in neonatal ventral hippocampal damaged rats.
2001 Mar
Functional coexpression of excitatory mGluR1 and mGluR5 on striatal cholinergic interneurons.
2001 Mar
(S)-3,4-DCPG, a potent and selective mGlu8a receptor agonist, activates metabotropic glutamate receptors on primary afferent terminals in the neonatal rat spinal cord.
2001 Mar
Patents

Sample Use Guides

Daily oral supplement of glycine at a dose of 0.5 g/kg divided in three doses during 8 weeks
Route of Administration: Oral
The excess of glycine inhibits the growth of many bacteria, and it is used as a nonspecific antiseptic agent due to its low level of toxicity in animals. The MIC at which 90% of strains are inhibited for glycine was almost 2.5 mg/ml for 31 strains of H. pylori, including CLR-resistant strains.
Substance Class Chemical
Created
by admin
on Fri Dec 15 19:39:56 GMT 2023
Edited
by admin
on Fri Dec 15 19:39:56 GMT 2023
Record UNII
F6B979BV8Z
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SODIUM GLYCINATE
INCI  
INCI  
Official Name English
GLYCINE, MONOSODIUM SALT
Common Name English
GLYCINE, SODIUM SALT (1:1)
Common Name English
SODIUM AMINOACETATE
Systematic Name English
SODIUM GLYCINATE [INCI]
Common Name English
SODIUM GLYCINE
Systematic Name English
ORISTAR SGLY
Brand Name English
GLYCINE SODIUM
Systematic Name English
SODIUM GLYCOCOLLATE
Common Name English
Code System Code Type Description
PUBCHEM
4684308
Created by admin on Fri Dec 15 19:39:56 GMT 2023 , Edited by admin on Fri Dec 15 19:39:56 GMT 2023
PRIMARY
ECHA (EC/EINECS)
227-842-3
Created by admin on Fri Dec 15 19:39:56 GMT 2023 , Edited by admin on Fri Dec 15 19:39:56 GMT 2023
PRIMARY
EPA CompTox
DTXSID50884211
Created by admin on Fri Dec 15 19:39:56 GMT 2023 , Edited by admin on Fri Dec 15 19:39:56 GMT 2023
PRIMARY
FDA UNII
F6B979BV8Z
Created by admin on Fri Dec 15 19:39:56 GMT 2023 , Edited by admin on Fri Dec 15 19:39:56 GMT 2023
PRIMARY
CAS
6000-44-8
Created by admin on Fri Dec 15 19:39:56 GMT 2023 , Edited by admin on Fri Dec 15 19:39:56 GMT 2023
PRIMARY
SMS_ID
300000033244
Created by admin on Fri Dec 15 19:39:56 GMT 2023 , Edited by admin on Fri Dec 15 19:39:56 GMT 2023
PRIMARY
RXCUI
541439
Created by admin on Fri Dec 15 19:39:56 GMT 2023 , Edited by admin on Fri Dec 15 19:39:56 GMT 2023
PRIMARY RxNorm
Related Record Type Details
PARENT -> SALT/SOLVATE